Investigating the role of apolipoprotein C3 in heart disease for patients with type 1 diabetes
Official title: Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
Funded at University of Washington · NIH-11013961 · Data updated 2026-11-12
This study is looking at how the protein APOC3 in your blood might affect your chances of developing heart disease if you have type 1 diabetes, and it’s also exploring a new treatment that could help lower APOC3 levels to keep your heart healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | January 5, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $808,164 |
| NIH project number | 5R01HL161829-04 |
| Project ID | NIH-11013961 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with type 1 diabetes who are at risk for cardiovascular disease.
✕Less likely to help
Patients without type 1 diabetes or those who do not have elevated cardiovascular disease risk may not benefit from this research.
What this research studies
This research focuses on understanding how apolipoprotein C3 (APOC3) levels influence the risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. By analyzing blood samples from a large group of patients, the study aims to determine if higher levels of APOC3 in certain lipoproteins can predict the onset of heart disease. Additionally, the research explores the potential of using an antisense oligonucleotide therapy to lower APOC3 levels and reduce CVD risk. This approach is based on previous findings that suggest lowering APOC3 can prevent heart disease progression in diabetic models.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of cardiovascular disease in patients with type 1 diabetes.
How similar studies have gone: Previous studies have shown promising results in reducing cardiovascular disease risk through similar approaches, indicating potential for success in this research.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Heinecke, Jay W — University of Washington
- Study coordinator: Heinecke, Jay W
Related research
Other NIH-funded projects on the same topics.
-
Technological and Educational Approaches to Restore Hypoglycemia Awareness in Type 1 Diabetes
A two-arm study in adults with type 1 diabetes tests whether high-tech glucose control plus education or targeted training can help people regain awareness of low blood sugar.
-
Techniques for restoring awareness of low blood sugar in adults with type 1 diabetes
A randomized trial compares different approaches to help adults with type 1 diabetes recognize when their blood sugar is dipping so they can act quickly.
-
Treating impaired hypoglycemia awareness in type 1 diabetes with targeted education and technology
This study tests two treatment approaches to help adults with type 1 diabetes who often don’t realize their blood sugar is getting too low, using a mix of technology and education in two large groups.
-
Helping people with type 1 diabetes regain awareness of dangerous lows
A UK study tests two different approaches to help adults with type 1 diabetes recognize and respond to low blood sugar by comparing a high-tech insulin system with targeted education.
-
How the pancreas environment affects insulin-producing cells in type 1 diabetes
Researchers are studying how the surrounding tissue of the pancreas and its proteins influence insulin-producing cells in people with type 1 diabetes.
-
Understanding how hypoglycemia awareness changes in adults with type 1 diabetes and how automated insulin delivery and exercise might help restore it
This study will look at adults with type 1 diabetes to see how their awareness of low blood sugar evolves over time and whether automated insulin delivery and high-intensity exercise can help restore that awareness.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.